Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Polyrizon Ltd. ( (PLRZ) ) has provided an update.
On December 2, 2025, Polyrizon Ltd. announced the successful completion of a significant manufacturing upscaling milestone for its nasal spray platform. This achievement transitions their PL-14 formulation from small-batch to large-scale production, ensuring high-quality standards are met. The milestone is crucial for supporting upcoming clinical trials expected in 2026 and aligns with regulatory standards in the USA and Europe, marking a step towards potential commercial readiness and addressing unmet needs in the nasal spray market.
More about Polyrizon Ltd.
Polyrizon Ltd. is a biotechnology company specializing in the development of innovative medical device hydrogels delivered as nasal sprays. These products form a hydrogel-based barrier in the nasal cavity to protect against viruses and allergens. The company’s proprietary Capture and Contain (C&C) hydrogel technology is designed to function as a ‘biological mask,’ and they are also exploring intranasal delivery of drugs through their Trap and Target (T&T) technology.
Average Trading Volume: 181,326
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.15M
For detailed information about PLRZ stock, go to TipRanks’ Stock Analysis page.